42.14
0.00
(0.00%)
At close: January 10 at 3:29:01 PM GMT+1
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Anish Bhatnagar M.D. | President, CEO, COO & Director | 1.03M | -- | 1970 |
| Mr. James H. MacKaness | Chief Financial Officer | 624.15k | -- | 1964 |
| Ms. Patricia C. Hirano M.P.H. | Senior Vice President of Regulatory Affairs | 480.79k | -- | 1966 |
| Mr. Jesse Schumaker | General Counsel | -- | -- | -- |
| Ms. Lauren Budesheim | Vice President of People | -- | -- | -- |
| Ms. Kristen Yen M.S. | Senior Vice President of Clinical Operations | 309.33k | -- | 1969 |
| Dr. Neil M. Cowen M.B.A., Ph.D. | Senior Vice President of Drug Development | -- | -- | -- |
| Ms. Meredith Manning M.B.A. | Chief Commercial Officer | -- | -- | 1972 |
| Dr. Michael Huang M.D. | Senior Vice President of Clinical Development | -- | -- | 1974 |
| Dr. Raymond W. Urbanski M.D., Ph.D. | Chief Development Officer | -- | -- | 1959 |
Soleno Therapeutics, Inc.
203 Redwood Shores Parkway
Suite 500
Redwood City, CA 94065
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 33
Description
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Corporate Governance
Soleno Therapeutics, Inc.’s ISS Governance QualityScore as of January 1, 2025 is 9. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 7; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
March 4, 2025 at 10:59 AM UTC - March 10, 2025 at 12:00 PM UTC
Soleno Therapeutics, Inc. Earnings Date
Recent Events
Recent Events Information Not Available
Related Tickers
UQ1.F uniQure N.V.
15.23
+0.03%
CXF.MU Chimerix Inc
3.1700
-5.09%
0K4.F Akero Therapeutics, Inc.
25.36
+0.71%
RADX Radiopharm Theranostics Limited
5.35
+30.17%
CGEM Cullinan Therapeutics, Inc.
11.19
+0.54%
OCS Oculis Holding AG
21.15
+13.10%
RZLT Rezolute, Inc.
4.9000
-5.95%
WVE Wave Life Sciences Ltd.
11.54
-7.68%
CYBN Cybin Inc.
8.89
-7.01%
JANX Janux Therapeutics, Inc.
46.76
-7.99%